Mark Thornton, MD, PhD, president of the Sarcoma Foundation of AmericaIn today's Wall Street Journal, Mark Thornton, M.D., Ph.D. deplores the FDA's decision on Dendreon's sipuleucal-T immunotherapy (Provenge vaccine). Dr. Thornton says "May 9, 2007, should be cited in the annals of cancer immunotherapy as Black Wednesday. Within an eight-hour period that day, the FDA succeeded in killing not one but two safe, promising therapies designed and developed to act by stimulating a patient's immune system against cancer. The FDA's hubris will affect the lives and possibly the life spans of cancer patients from nearly every demographic, from elderly men with prostate cancer to young children with the rarest of bone cancers."
...continue reading "“Black Wednesday at the FDA” – WSJ"